Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
Vanita Noronha,Vijay Patil,Pankaj Chaturvedi,Vijayalakshmi Mathrudev,Nandini Menon,Atanu Bhattacharjee,Ajay Singh,Zoya Peelay,Shatabdi Chakraborty,Monica Jadhav,Mitali Alone,Priyanka Bhagyavant,Manali Kolkur,Sujay Srinivas,Sudeep Das,Somnath Roy,Tanmoy Mandal,Hollis Dsouza,Saswata Saha,Rahul Rai,Anne Srikanth,Darshit Shah,Arif Khan,Hemanth Muthuluri,Amit Kumar,Amit Agarwal,Anu Rajpurohit,Vasu Babu Goli,Anbarasan Sekar,Anoop Mantri,Aditya Pavan Kumar Kanteti,Swaratika Majumdar,Satvik Khaddar,Ramnath Shenoy,Prahlad Elamarthi,Narmadha Rathnasamy,Lakhan Kashyap,George Abraham,Naveen Booma,Vijay Simha,Devendra Chaukar,Prathamesh Pai,Sudhir Nair,Sarbani Laskar,Kavita Nawale,Priyanka Naidu,Sushmita Salian,Priyanka Shelar,Ravinarayan Raulo,Sachin Babanrao Dhumal,Kumar Prabhash
DOI: https://doi.org/10.1016/j.ejca.2024.113560
IF: 10.002
2024-01-22
European Journal of Cancer
Abstract:Background Neoadjuvant chemotherapy (NACT) with TPF (docetaxel, cisplatin, and 5FU) is one of the treatment options in very locally advanced oral cancer with a survival advantage over PF (cisplatin and 5FU). TP (docetaxel and cisplatin) has shown promising results with a lower rate of adverse events but has never been compared to TPF. Methods In this phase 3 randomized superiority study, adult patients with borderline resectable locally advanced oral cancers were randomized in a 1:1 fashion to either TP or TPF. After the administration of 2 cycles, patients were evaluated in a multidisciplinary clinic and further treatment was planned. The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) and adverse events. Results 495 patients were randomized in this study, 248 patients in TP arm and 247 in TPF arm. The 5-year OS was 18.5% (95% CI 13.8-23.7) and 23.9% (95%CI 18.1-30.1) in TP and TPF arms, respectively (Hazard ratio 0.778; 95% CI 0.637-0.952; P=0.015). Following NACT, 43.8% were deemed resectable, but 34.5% underwent surgery. The 5-year OS were 50.7% (95% CI 41.5-59.1) and 5% (95%CI 2.9-8.1), respectively, in the surgically resected versus unresected cohort post NACT (P<0.0001). Grade 3 or above adverse events were seen in 97 (39.1%) and 179 (72.5%) patients in the TP and TPF arms, respectively (P<0.0001). Conclusion NACT with TPF has a survival benefit over TP in borderline resectable oral cancers, with an increase in toxicity which is manageable. Patients who undergo surgery achieve a relatively good, sustained survival.
oncology